DDAHCRISPRプラスミド
サンタクルスバイオテクノロジー社は遺伝子サイレンシング用のCRISPR/Cas9ノックアウト及びCRISPR Double Nickaseプラスミドを含め、広範囲の遺伝子編集製品を提供しております。DDAH遺伝子サイレンサーは、DDAH CRISPR/Cas9ノックアウトプラスミドとDDAHDouble Nickaseプラスミドとして利用可能です。遺伝子活性化用のDDAHCRISPR/dCas9 Activationプラスミド及びCRISPR Lenti Activationシステムも利用できます。遺伝子サイレンサーと活性化剤はタンパク質の検出に使用された抗体と組み合わせた遺伝子研究に有用です。
DDAH CRISPR Knockout, HDR and Double Nickase Plasmids
| Empty Table Header | 製品名 | CATALOG # | Species | アプリケーション | MARKER | 引用文献 | レーティング |
|---|---|---|---|---|---|---|---|
DDAH I CRISPR/Cas9 KOプラスミド (h) | sc-402719 | h | Gene Knockout | GFP | 0 | ||
DDAH I HDRプラスミド (h) | sc-402719-HDR | h | Homology Directed Repair | Puromycin | 0 | ||
DDAH I Double Nickaseプラスミド (h) | sc-402719-NIC | h | Gene Knockout | Puromycin | 0 | ||
DDAH I Double Nickaseプラスミド (h2) | sc-402719-NIC-2 | h | Gene Knockout | Puromycin | 0 | ||
DDAH I CRISPR/Cas9 KOプラスミド (m) | sc-427341 | m | Gene Knockout | GFP | 0 | ||
DDAH I HDRプラスミド (m) | sc-427341-HDR | m | Homology Directed Repair | Puromycin | 0 | ||
DDAH I Double Nickaseプラスミド (m) | sc-427341-NIC | m | Gene Knockout | Puromycin | 0 | ||
DDAH I Double Nickaseプラスミド (m2) | sc-427341-NIC-2 | m | Gene Knockout | Puromycin | 0 | ||
DDAH II CRISPR/Cas9 KOプラスミド (h) | sc-403032 | h | Gene Knockout | GFP | 0 | ||
DDAH II HDRプラスミド (h) | sc-403032-HDR | h | Homology Directed Repair | Puromycin | 0 | ||
DDAH II Double Nickaseプラスミド (h) | sc-403032-NIC | h | Gene Knockout | Puromycin | 0 | ||
DDAH II Double Nickaseプラスミド (h2) | sc-403032-NIC-2 | h | Gene Knockout | Puromycin | 0 | ||
DDAH II CRISPR/Cas9 KOプラスミド (m) | sc-424553 | m | Gene Knockout | GFP | 0 | ||
DDAH II HDRプラスミド (m) | sc-424553-HDR | m | Homology Directed Repair | Puromycin | 0 | ||
DDAH II Double Nickaseプラスミド (m) | sc-424553-NIC | m | Gene Knockout | Puromycin | 0 | ||
DDAH II Double Nickaseプラスミド (m2) | sc-424553-NIC-2 | m | Gene Knockout | Puromycin | 0 |
DDAH CRISPR Activation Products
| Empty Table Header | 製品名 | CATALOG # | Species | アプリケーション | MARKER | 引用文献 | レーティング |
|---|---|---|---|---|---|---|---|
DDAH I CRISPR Activationプラスミド (h) | sc-402719-ACT | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH I CRISPR Activationプラスミド (h2) | sc-402719-ACT-2 | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH I Lentiviral Activation Particles (h) | sc-402719-LAC | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH I Lentiviral Activation Particles (h2) | sc-402719-LAC-2 | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH I CRISPR Activationプラスミド (m) | sc-427341-ACT | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH I CRISPR Activationプラスミド (m2) | sc-427341-ACT-2 | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH I Lentiviral Activation Particles (m) | sc-427341-LAC | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH I Lentiviral Activation Particles (m2) | sc-427341-LAC-2 | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH II CRISPR Activationプラスミド (h) | sc-403032-ACT | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH II CRISPR Activationプラスミド (h2) | sc-403032-ACT-2 | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH II Lentiviral Activation Particles (h) | sc-403032-LAC | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH II Lentiviral Activation Particles (h2) | sc-403032-LAC-2 | h | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH II CRISPR Activationプラスミド (m) | sc-424553-ACT | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH II CRISPR Activationプラスミド (m2) | sc-424553-ACT-2 | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH II Lentiviral Activation Particles (m) | sc-424553-LAC | m | Gene Activation | Puro, Blast, Hygro | 0 | ||
DDAH II Lentiviral Activation Particles (m2) | sc-424553-LAC-2 | m | Gene Activation | Puro, Blast, Hygro | 0 |